2009 Compensation Information for Named Executive Officers of Seattle Genetics, Inc.

Summary

This document outlines the annual base salaries and bonus information for 2008 and 2009 for the named executive officers of Seattle Genetics, Inc. It lists the specific compensation amounts for each officer, including base salary, bonuses awarded for 2008, and target bonus percentages for 2009. The agreement also references where to find information about director compensation. The key obligation is the disclosure of executive compensation details as required by securities laws.

EX-10.56 11 dex1056.htm 2009 COMPENSATION INFORMATION FOR NAMED EXECUTIVE OFFICERS 2009 Compensation Information for Named Executive Officers

Exhibit 10.56

Named Executive Officer Compensation Information

The following table sets forth the annual base salaries for 2008 and 2009 for the “named executive officers” (as defined under applicable securities laws) of Seattle Genetics, Inc. (the “Company”). The table below also sets forth the bonuses awarded to the Company’s named executive officers for the 2008 fiscal year under the Company’s 2008 Senior Executive Annual Bonus Plan. The 2009 target bonuses (based on a percentage of base salary) for the Company’s named executive officers under the Company’s 2009 Senior Executive Annual Bonus Plan are also set forth in the table below.

 

Name and Title

   2008 Base Salary    2008 Bonus    2009 Base Salary    2009 Target Bonus
Percentage
 

Clay B. Siegall, Ph.D.
President & Chief Executive Officer

   $ 575,000    $ 359,375    $ 602,350    50 %

Todd E. Simpson
Chief Financial Officer

   $ 306,200    $ 140,852    $ 313,900    40 %

Eric L. Dobmeier
Chief Business Officer

   $ 354,550    $ 174,439    $ 370,550    40 %

Thomas C. Reynolds
Chief Medical Officer

   $ 352,050    $ 178,841    $ 369,700    40 %

Morris Rosenberg
Executive Vice President, Development

   $ 300,050    $ 110,718    $ 318,300    35 %

Director Compensation Information

Please see the section entitled “Director Compensation” in the Company’s 2008 definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 16, 2008, for a description of the compensation provided to members of the Company’s Board of Directors.